Sarepta Therapeutics, Inc. - Common Stock (SRPT)

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced positive topline results from Part 2 of EMBARK (Study SRP-9001-301), a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study of ELEVIDYS (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported preliminary* fourth quarter and full-year 2024 net product revenue and cash on hand as of December 31, 2024, as part of its presentation today at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, Calif. on Monday, Jan. 13, 2025 at 12:00 p.m. E.T. / 9:00 a.m. P.T. Following the presentation there will be a Q&A session starting at 12:20 p.m. E.T. / 9:20 a.m. P.T.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 8 individuals hired by Sarepta in December 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that enrollment and dosing is complete in EMERGENE (Study SRP-9003-301), a Phase 3 clinical trial of SRP-9003 (bidridistrogene xeboparvovec). SRP-9003 is an investigational gene therapy for the treatment of limb-girdle muscular dystrophy Type 2E/R4 (LGMD2E/R4), or beta-sarcoglycanopathy. EMERGENE is a global study, and the primary endpoint is the biomarker expression of beta-sarcoglycan protein, the absence of which is the sole cause of LGMD2E/R4.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 14 individuals hired by Sarepta in November 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. NASDAQ: ARWRNASDAQARWR)

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the third quarter 2024.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on October 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 15 individuals hired by Sarepta in October 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report third quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, Nov. 6, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its third quarter 2024 financial results.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on September 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 28 individuals hired by Sarepta in September 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Capricor Therapeutics Inc. (NASDAQCAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will present at the 29th Annual Congress of the World Muscle Society 2024 Congress (WMS 2024), taking place Oct. 8-12, 2024, in Prague, Czechia.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced the appointment of Deirdre P. Connelly to its Board of Directors. Ms. Connelly is a well-regarded executive with more than 30 years of experience in the pharmaceutical industry. Following Connelly’s appointment, Sarepta’s Board will comprise nine directors, eight of whom are independent.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced 25 recipients of Route 79, The Duchenne Scholarship Program for the 2024-2025 academic year. Of the academic scholarships, 20 will be awarded to individuals living with Duchenne muscular dystrophy and five to siblings of individuals living with Duchenne. Each recipient will receive a scholarship of up to $5,000.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on August 30, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 20 individuals hired by Sarepta in August 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference at the New York Marriott Marquis in New York, NY. on Friday, Sept. 6, 2024, at 9:15 a.m. E.T.

Avidity Biosciences' stock has performed incredibly well in 2024. Its Duchenne muscular dystrophy drug is showing strong results in trials.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter 2024.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on July 31, 2024 (the “Grant Date”) that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 19 individuals hired by Sarepta in July 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, August 7, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2024 financial results.

AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on June 28, 2024 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2024 Employment Commencement Incentive Plan, as a material inducement to employment to 23 individuals hired by Sarepta in June 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

Sarepta Therapeutics' expanded FDA approval for its DMD gene therapy, Elevidys, propels the company into a dominant position in the rare disease market.

Sarepta Therapeutics, Inc. (NASDAQSRPT), the leader in precision genetic medicine for rare diseases, today announced U.S. Food and Drug Administration (FDA) approval of an expansion to the labeled indication for ELEVIDYS (delandistrogene moxeparvovec-rokl) to include individuals with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene who are at least 4 years of age. Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients. The FDA granted accelerated approval for non-ambulatory patients. Continued approval for non-ambulatory Duchenne patients may be contingent upon verification of clinical benefit in a confirmatory trial. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.